‘Breakthrough’ Drugs Get ‘Road-MaPP’ – Complete With Communication Timetable
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
CDER Manual of Policy and Procedures describes specific actions FDA review staff will take once a product has received “breakthrough therapy” designation, with an emphasis on more meetings, more frequently.
You may also be interested in...
Zykadia Expedited Timeline Challenged By Late-Breaking GMP Concern
CDER Director Woodcock was quickly consulted about a manufacturing concern at a foreign site that emerged shortly before FDA’s target action date for Novartis’ ceritinib NDA as the agency strove to avoid delaying approval of the “breakthrough” lung cancer therapy.
Sovaldi NDA Review Marred By Manufacturing Compliance Issues
Faced with the prospects of FDA non-approval of its priority review hepatitis C drug sofosbuvir, Gilead withdrew a foreign API manufacturer and one of its own testing facilities from the NDA late in the review process due to Good Manufacturing Practice violations and data integrity concerns.
“Breakthrough Therapy” Development Speed May Be Tempered By Manufacturing Hurdles
Sponsors and FDA also will have to work through issues related to companion diagnostics to prevent treatments designated under the FDASIA’s new expedited development pathway from being delayed. Harmonization with foreign regulators is essential to making the pathway work, stakeholders say.